Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
Peddi V, Marder B, Gaite L, Oberholzer J, Goldberg R, Pearson T, Yang H, Allamassey L, Polinsky M, Formica R. Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression. Transplantation Direct 2023, 9: e1419. PMID: 36700062, PMCID: PMC9820789, DOI: 10.1097/txd.0000000000001419.Peer-Reviewed Original ResearchBiopsy-proven acute rejection rateAcute rejection ratesAcute rejectionITT populationMycophenolate mofetilDe novo renal transplant recipientsBiopsy-proven acute rejectionDe novo renal transplantHigher acute rejection ratesNovo renal transplant recipientsRabbit antithymocyte globulin inductionCalcineurin inhibitor-based immunosuppressionAntithymocyte globulin inductionLymphocyte-depleting inductionGood renal functionPosttransplant lymphoproliferative disorderRenal transplant recipientsPhase 2 studyGlomerular filtration rateUnexpected adverse eventsEpstein-Barr virusCorticosteroid withdrawalGlobulin inductionGraft lossMaintenance regimen